medRxiv : the preprint server for health sciences · 2025
Plasma biomarkers, brain amyloid pathology, and cortical thickness in a diverse middle-aged community cohort: the HCP-CoBRA study.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brodman Shayna T, Heaton Nicholas, Triana-Baltzer Gallen, Zeng Xuemei, Gogola Alexandra, Kamboh M Ilyas, Villemagne Victor L, Lopez Oscar L, Kolb Hartmuth, Deek Rebecca A, Cohen Ann D, Karikari Thomas K
Аннотация
INTRODUCTION: We evaluated plasma biomarker association with, and classification accuracies for, Aβ-PET and cortical thickness in the biracial HCP-CoBRA cohort (53% B/AA and 47% NHW).
METHODS: In n=218 participants (age 62 [range: 57-71] years, 65% female and 15% Aβ PET-positive), plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL, Aβ42/Aβ40) were compared to Aβ-PET and MRI neuroimaging indicators.
RESULTS: P-tau217 (Janssen and ALZpath [AUCs=0.915-0.919]) had high sensitivity and specificity (>85%) for Aβ-PET status. All biomarkers except p-tau231 ruled out Aβ-pathology (NPV>95%) but only Janssen p-tau217+ was good for confirmation (PPV=0.909). Plasma biomarkers performed poorly for predicting cortical thickness but were elevated according to joint Aβ-PET-neurodegeneration profiles. Biomarker accuracies for Aβ-PET positivity were unaffected by self-identified race, except ALZpath p-tau217(p=0.024). However, correlations with Aβ-PET varied by self-identified race.
DISCUSSION: P-tau217 is a promising tool for Alzheimer's disease-related Aβ pathology in older/middle-aged individuals. However, apparent race-related performances should be further studied.
METHODS: In n=218 participants (age 62 [range: 57-71] years, 65% female and 15% Aβ PET-positive), plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL, Aβ42/Aβ40) were compared to Aβ-PET and MRI neuroimaging indicators.
RESULTS: P-tau217 (Janssen and ALZpath [AUCs=0.915-0.919]) had high sensitivity and specificity (>85%) for Aβ-PET status. All biomarkers except p-tau231 ruled out Aβ-pathology (NPV>95%) but only Janssen p-tau217+ was good for confirmation (PPV=0.909). Plasma biomarkers performed poorly for predicting cortical thickness but were elevated according to joint Aβ-PET-neurodegeneration profiles. Biomarker accuracies for Aβ-PET positivity were unaffected by self-identified race, except ALZpath p-tau217(p=0.024). However, correlations with Aβ-PET varied by self-identified race.
DISCUSSION: P-tau217 is a promising tool for Alzheimer's disease-related Aβ pathology in older/middle-aged individuals. However, apparent race-related performances should be further studied.